drugset
drugset / Trial / NCT05474885

BCMA-CD19 cCAR T Cell Treatment of Relapsed/Refractory Systemic Lupus Erythematosus (SLE)

NCT05474885 ↗

Phase 1 Unknown 15 enrolled iCell Gene Therapeutics iCAR Bio Therapeutics Ltd. China · collab
NaSequentialOpen-labelTreatment

Summary

This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of BCMA-CD19 cCAR T cells in patients with relapsed and/or refractory SLE.

Timeline

Start
2022-04-01
Primary completion
2025-04-30
Completion
2025-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject BCMA-CD19 cCAR T cells Cell therapy — Intravenous

Indications

systemic lupus erythematosus